SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition

SMARCA4型 ARID1A型 SMARCB1型 医学 癌症研究 免疫检查点 瑞士/瑞士法郎 表型 染色质重塑 免疫系统 突变 癌症 肿瘤科 内科学 基因 免疫疗法 染色质 免疫学 生物 遗传学
作者
Joao V. Alessi,Biagio Ricciuti,Liam Flinn Spurr,Hersh V. Gupta,Yvonne Y. Li,Carolyn Glass,Mizuki Nishino,Andrew D. Cherniack,James R. Lindsay,Bijaya Sharma,Kristen D. Felt,Scott J. Rodig,Michael L. Cheng,Lynette Marie Sholl,Mark Magdi Awad
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:16 (7): 1176-1187 被引量:155
标识
DOI:10.1016/j.jtho.2021.03.024
摘要

The SWItch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling complex acts as a regulatory component of transcription, and inactivating mutations (muts) within the complex are implicated in genomic instability, higher tumor mutational burden, and an aggressive cancer phenotype. Whether SMARCA4 and other SWI/SNF alterations are independent prognostic factors or associated with clinical outcomes to immune checkpoint inhibitors (ICIs) in NSCLC remains unclear.We collected clinicopathologic and genomic data from patients with NSCLC who underwent targeted next-generation sequencing at the Dana-Farber Cancer Institute. Tumors were characterized on the basis of the presence or absence of muts across a set of six SWI/SNF genes (ARID1A, ARID1B, ARID2, PBRM1, SMARCA4, and SMARCB1).Of 2689 patients with NSCLC, 20.6% (N = 555) had SWI/SNF genomic alterations. Compared with SWI/SNF wild-type (wt) NSCLC, patients with SWI/SNF-mutant NSCLCs had a lower prevalence of concurrent targetable driver muts (33.2% versus 22.2%; p < 0.001), a higher tumor mutational burden (median 8.5 versus 12.2 muts/megabase; p < 0.001), and a shorter median overall survival (mOS) from the time of advanced disease diagnosis (25.0 versus 19.3 mo, p = 0.01); the detrimental effect in OS seemed to be largely driven by SMARCA4 muts (mOS: 25.0 for SMARCA4 wt versus 15.6 mo for SMARCA4 mutant; p < 0.001). Among 532 patients who received ICIs, 25.5% (N = 136) harbored SWI/SNF muts. From the start of immunotherapy, there was no difference in objective response rate (ORR = 19.9% versus 25.0%, p = 0.2), median progression-free survival (mPFS = 3.0 versus 3.0 mo, hazard ratio [HR] = 0.96 [95% confidence interval [CI] = 0.77-1.18], p = 0.7), or mOS (13.1 versus 9.5 mo, HR = 0.81 [95% CI: 0.64-1.02], p = 0.07) in SWI/SNF-wt versus SWI/SNF-mutant NSCLC, respectively. Nevertheless, among KRAS-mutant NSCLCs treated with ICIs (N = 176), a concurrent SWI/SNF mut (N = 39) conferred a numerically lower ORR (21.9% versus 12.8%, p = 0.2), a significantly shorter mPFS (4.1 versus 1.8 mo, HR = 0.57 [95% CI: 0.38-0.84], p = 0.005), and a significantly shorter mOS (15.5 versus 8.2 mo, HR = 0.56 [95% CI: 0.36-0.86], p = 0.008). The deleterious effect on immunotherapy outcomes in KRAS-mutant NSCLC was most pronounced in the SMARCA4-mutant subset (N = 17), with a lower ORR (22% versus 0%, p = 0.03), a significantly shorter mPFS (4.1 versus 1.4 mo, HR = 0.25 [95% CI: 0.14-0.42], p < 0.001), and a significantly shorter mOS (15.1 versus 3.0 mo, HR = 0.29 [95% CI: 0.17-0.50], p < 0.001) compared with SMARCA4-wt KRAS-mutant NSCLCs.Although there were no associations between SWI/SNF mut status and immunotherapy efficacy in the overall NSCLC cohort, the presence of a SMARCA4 alteration may confer a worse outcome to immunotherapy among KRAS-mutant NSCLCs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
perper完成签到,获得积分10
2秒前
纯真采蓝发布了新的文献求助10
2秒前
大轩发布了新的文献求助10
2秒前
2秒前
NexusExplorer的应助被开心德地采纳,获得10
3秒前
molihuakai的应助被1111111采纳,获得10
4秒前
4秒前
More的应助被wg采纳,获得10
4秒前
ZLR完成签到,获得积分10
4秒前
杨露茜发布了新的文献求助10
5秒前
keep发布了新的文献求助10
5秒前
Lingyu发布了新的文献求助10
6秒前
7秒前
lin的应助被hy采纳,获得10
7秒前
李爱国的应助被fff采纳,获得10
8秒前
8秒前
10秒前
脑洞疼的应助被QL采纳,获得30
10秒前
spc68的应助被李梦晓采纳,获得10
10秒前
卷卷完成签到 ,获得积分10
12秒前
asdfqwer发布了新的文献求助50
13秒前
JamesPei的应助被ding采纳,获得10
14秒前
温暖的鼠标完成签到,获得积分10
15秒前
1111111完成签到,获得积分10
15秒前
15秒前
16秒前
钟意发布了新的文献求助10
16秒前
Ava的应助被spell采纳,获得10
17秒前
SoilMan发布了新的文献求助10
17秒前
18秒前
20秒前
开心消消乐完成签到 ,获得积分10
21秒前
去冰三分甜完成签到,获得积分10
21秒前
23秒前
23秒前
24秒前
蜡笔完成签到 ,获得积分10
24秒前
共享精神的应助被wwrrqq采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188785
求助须知:如何正确求助?哪些是违规求助? 9576421
关于积分的说明 21847553
捐赠科研通 7786814
什么是DOI,文献DOI怎么找? 3435417
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482366